Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Misagh Karimi

Hematology Oncology | Hematology | Oncology
UCI Health
Uc Regents
101 The City Dr S, 
Orange, CA 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
UCI Health
Uc Regents
101 The City Dr S, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Misagh Karimi is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Karimi is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Paget Disease of the Breast.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
University Of California Irvine Medical Center
Hoag Memorial Hospital Presbyterian
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UC REGENTS
101 The City Dr S, Orange, CA 92868
Call: 714-456-7002

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, PEG-Liposomal Doxorubicin
Study Phase: Phase 1
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Letrozole, Palbociclib, Pembrolizumab
Study Phase: Phase 2
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Drug, Other
Study Drugs: Trametinib, Trifluridine, Tipiracil Hydrochloride
Study Phase: Phase 1
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Anastrozole, Doxorubicin Hydrochloride, Exemestane, Letrozole, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Enobosarm, Pembrolizumab
Study Phase: Phase 2
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other
Study Drugs: Aromatase Inhibitor, Ribociclib
Study Phase: Phase 2
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Other, Drug
Study Drug: Neratinib
Study Phase: Phase 2
View 6 Less Clinical Trials

6 Total Publications

Proposed Implementation of a Patient-Centered Self-Assessment Tool for Patients with Neuroendocrine Tumors among Academic and Community Practice Sites: The City of Hope Model.
Proposed Implementation of a Patient-Centered Self-Assessment Tool for Patients with Neuroendocrine Tumors among Academic and Community Practice Sites: The City of Hope Model.
Journal: Journal of clinical medicine
Published: December 15, 2022
View All 6 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (34.5 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Robert Figlin is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Figlin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-456-7004
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nataliya Mar is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Mar has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, Uci Dept Of Medicine, 
Orange, CA 
 (0.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Rezazadeh-Kalebasty is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Rezazadeh-Kalebasty is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karimi's expertise for a condition
ConditionClose
    • Distinguished
    • Breast Cancer
      Dr. Karimi is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Karimi is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Karimi is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Paget Disease of the Breast
      Dr. Karimi is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Pleuropulmonary Blastoma
      Dr. Karimi is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Advanced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Karimi is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Karimi is
      Advanced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Angiosarcoma
      Dr. Karimi is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Childhood Acute Myeloid Leukemia
      Dr. Karimi is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    • Childhood Iron Deficiency Anemia
      Dr. Karimi is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Karimi is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    View All 24 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Karimi is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acute Erythroid Leukemia (AEL)
      Dr. Karimi is
      Experienced
      . Learn about Acute Erythroid Leukemia (AEL).
      See more Acute Erythroid Leukemia (AEL) experts
    • Acute Mountain Sickness
      Dr. Karimi is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Karimi is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Karimi is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Karimi is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved